Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Manipulating master molecule shown to disrupt vascular environment for tumors in animal models

16.06.2004


Targeting a master molecule that helps cancer cells survive when blood oxygen levels are low may offer a potentially powerful strategy for blocking tumor growth, say researchers at The University of Texas M. D. Anderson Cancer Center.



The molecule, "hypoxia-inducible factor 1," or HIF-1, controls production of a number of other proteins, such as vascular endothelial growth factor (VEGF), which work in concert to help nurture these stressed cancer cells. Researchers show that genetically jamming HIF-1 damages the vascular microenvironment and impairs tumor growth, according to the study, published in the June 16th issue of Journal of the National Cancer Institute.

The resarchers found, for example, that while new blood vessels will still grow in tumors when HIF-1 is blocked, the blood vessels were small, with thin walls, and no lumen -- the passage through which blood flows. The tumors were only about 1/10th the size of cancerous masses seen in a group of control mice.


Although the researchers caution that their study was conducted only in animals, they say the findings are of note because HIF-1, as a master molecule, could prove to be a target for anti-cancer drugs.

"We have shown, genetically, that inhibiting HIF-1 significantly impairs tumor growth, so it seems that targeting HIF-1 might offer a great deal of promise in regulating the growth of solid tumors," says the study’s senior author, Lee Ellis, M.D., a professor in the Departments of Surgical Oncology and Cancer Biology at M. D. Anderson.

The value of inhibiting this "angiogenic" pathway has already been shown in federal approval of the drug Avastin, an antibody that binds VEGF and prevents its effect on angiogenesis. But there are no drugs currently available or in testing that specifically target HIF-1, Ellis says, so clinical validation of these findings in patients will probably be years away.

"The next step in the process is to seek or develop agents that specifically target HIF-1; until then, this work is limited to animal models," he says.

The study focused on HIF-1’s role in gastric (stomach) cancer, but the master molecule is believed to play a role in growth and metastasis of colon, pancreatic and other cancers, and is directly associated with development of renal cell carcinoma, says Ellis.

Cells continually produce HIF-1 proteins, but they are quickly degraded if the cell is healthy, receiving a sufficient supply of oxygen. If the cell become hypoxic (lacking oxygen), HIF-1 is not destroyed. It binds with a partner protein and moves into the cell’s nucleus, where it turns on a large number of genes that help support the cell in a relatively caustic environment "of low oxygen and nutrients, and increased acidity," says Ellis. "When cells grow faster than blood vessels, such as when cancer develops and there is not enough oxygen and glucose around, HIF-1 becomes active, pushing the growth of new blood vessels."

In the study, the researchers conducted a series of both cell culture and mouse experiments; previous studies conducted in one or the other system have been contradictory. They transferred a gene into human gastric cancer cells that would not allow HIF-1 to initiate gene activation in the cell nucleus, and then found that in hypoxic conditions, VEGF secretion was not increased, showing that HIF-1 controlled VEGF levels.

They then conducted animal studies, including one in which the altered cancer cells were injected into the stomach wall. Gastric tumors grew in both a control group and in the experimental group of animals. At 22 days, tumors growing in the experimental group, in cells that expressed low levels of HIF-1, were significantly smaller than those growing in the control group.

"We were able to markedly inhibit tumor growth, and we also found something interesting," says Ellis. "The number of blood vessels between the groups was unchanged, yet in experimental mice, the vessels were smaller, and without a lumen. They didn’t appear to be able to remain open. They were not ’good’ vessels."

The investigators evaluated the structure of these altered vessels and found they didn’t contain many pericytes. Normal blood vessels have endothelial cells surrounded by pericytes, which provide structurally rigidity and also modulate endothelial cell survival. "We found that the endothelial cells had little pericyte coverage in tumors with decreased HIF-1 activity, suggesting that HIF-1 not only regulates molecules that mediate endothelial cell function, but also pericyte function," Ellis says.

These results suggest that HIF-1 not only regulates VEGF expression in cancer cells, he says, "but also contributes to the formation of a complex proangiogenic microenvironment in tumors, affecting both the structure and function of blood vessels."


The study was supported by grants from the National Institutes of Health. Co-authors include, from M. D. Anderson’s Department of Cancer Biology: Oliver Stoeltzing, M.D., Fan Fan, BS, Weinbiao Liu, M.D., and Anna Belcheva, M.D.; from M. D. Anderson’s Department of Surgical Oncology: Marya McCarty, Ph.D., and Jane Wey, M.D. Another co-author, Gregg Semenza, M.D., Ph.D., at the Johns Hopkins University School of Medicine, is a leading expert on HIF-1 research.

Laura Sussman | EurekAlert!

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>